What Fueled The Previous Growth In The Single-Cell Genome Sequencing Market?
The single-cell genome sequencing market has seen considerable growth due to a variety of factors.
•The market for single-cell genome sequencing has seen swift expansion in recent times. The market size is projected to rise from $2.49 billion in 2024 to $2.84 billion in 2025, with a compound annual growth rate (CAGR) of 13.9%.
The swell in growth during the historical period can be credited to enhanced knowledge of genetic heterogeneity, surged demand for personalized medicine, augmented cancer research, growth in the occurrence of infectious diseases, and boosted expenditure on healthcare.
What Is The Expected Growth In The Single-Cell Genome Sequencing Market Size?
The single-cell genome sequencing market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipations are high for the single-cell genome sequencing market to experience an accelerated growth in the coming years. The market is projected to surge to $5.04 billion by 2029, with a CAGR of 15.4%.
Factors set to drive this growth in the forecast period range from the rising occurrences of autoimmune diseases and neurological disorders, to increased government support and funding, the advent of contract research organizations (cros), and heightened understanding of the potential of scrna-seq. Key trends to observe in this period comprise advancements in single-cell sequencing technologies, the expansion of single-cell multi-omics technologies, joint initiatives aimed at quickening advancements, innovative solutions, and strategic alliances among key market players.
What Main Forces Are Fueling Expansion In The Single-Cell Genome Sequencing Market?
The rising incidence of cancer is predicted to boost the development of the single-cell genome sequencing market. The term cancer broadly refers to diverse diseases characterized by abnormal cell growth and uncontrolled cellular division, which is a result of modifications in genes that oversee cell division and regulate cell functionality. As cancer is marked by genetic variations, single-cell genome sequencing can reveal the genetic shifts that happen within individual cancer cells. For example, in January 2023, the American Cancer Society, a US-based organization dedicated to fighting cancer, recorded roughly 1.9 million fresh cancer diagnoses and 609,360 cancer-related deaths in the US in 2022. Furthermore, an estimated 27.5 million new cancer cases and 16.3 million deaths from cancer are projected to occur by 2040. Thus, the escalating occurrence of cancer is expected to catalyze the expansion of the single-cell genome sequencing market.
What Are The Primary Segments In The Global Single-Cell Genome Sequencing Market?
The single-cell genome sequencing market covered in this report is segmented –
1) By Type: Instruments, Reagents
2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Quantitative Polymerase Chain Reaction (qPCR), Microarray, Multiple Displacement Amplification (MDA)
3) By Disease Area: Cancer, Immunology, Prenatal Diagnosis, Neurobiology, Microbiology, Other Disease Areas
4) By Application: Circulating Cells, Cell Differentiation Or Reprogramming, Genomic Variation, Subpopulation Characterization, Other Applications
5) By End User: Academic Research Laboratories, Biotechnology Biopharmaceutical Companies, Clinics, Other End Users
Subsegments:
1) By Instruments: Single-Cell Isolation Systems, Sequencing Platforms, Automation And Robotic Systems
2) By Reagents: Library Preparation Kits, Amplification Reagents, DNA Extraction Kits, Quality Control Reagents
Pre-Book The Single-Cell Genome Sequencing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Single-Cell Genome Sequencing Market?
The surge in technological innovations is an emerging trend in the single-cell genome sequencing sector. The primary players in this market are concentrating their efforts on the creation of technologically superior solutions to consolidate their market position. For example, in May 2023, Mission Bio Inc., a US-based firm offering a single-cell multi-omics platform, which merges genotype and phenotype for cancer research and biomarker development, unveiled its Tapestri Genome Editing Solution, a comprehensive product for genome editing analysis. This innovative approach is expected to serve as a more potent tool for the creation of future gene-modified drugs by facilitating single-cell insights that can alter efficacy and safety.
Who Are the Key Players in the Single-Cell Genome Sequencing Market?
Major companies operating in the single-cell genome sequencing market include:
• F Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• DH Life Sciences LLC.
• Becton Dickinson And Company (BD)
• Agilent Technologies Inc.
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN GmbH
• Bio-Techne Corporation
• BGI Genomics Co. Ltd.
• Fulgent Genetics Inc.
• 10x Genomics Inc.
• Promega Corporation
• Takara Bio Inc.
• Oxford Nanopore Technologies PLC
• Pacific Biosciences of California Inc.
• Standard BioTools Inc.
• Singleron Biotechnologies
• MGI Tech Co. Ltd
• GENEWIZ Inc.
• Mission Bio Inc.
• Zymo Research Corporation
• Menarini Silicon Biosystems SpA
• Novogene Co. Ltd.
• RareCyte Inc.
• Fluxion Biosciences Inc.
• Single Cell Discoveries B.V.
• Parse Biosciences Inc.
• BioSpyder Technologies Inc.
• SeqWell Inc.
What Is The Most Dominant Region In The Single-Cell Genome Sequencing Market?
North America was the largest region in the single-cell genome sequencing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single-cell genome sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
